Luveris market growth tied to rising infertility treatment demand

The Luveris market is expanding as infertility rates rise and fertility clinics invest more in advanced hormonal therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Luveris demand is closely linked to the broader fertility treatment market, where rising infertility rates are increasing the use of hormonal therapies and assisted reproductive technologies. - The market outlook matters for fertility clinics, healthcare systems and drug makers focused on ovulation induction and reproductive endocrinology.

What happened: - The Business Research Company released its Luveris Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Luveris market gained traction in the historic period because of rising infertility, more IVF clinics, greater awareness of hormonal infertility treatments, wider access to recombinant hormone therapies and progress in reproductive endocrinology. - The forecast period is expected to benefit from increasing maternal age, more fertility-clinic investment, wider use of personalized reproductive medicine, expansion of fertility preservation services and growing demand for advanced hormonal therapies.

The details: - Luveris, or lutropin alfa, is a lab-made form of luteinizing hormone used for women with severe luteinizing hormone deficiencies or those undergoing assisted reproduction such as IVF. - Luveris works by replicating natural LH, supporting ovarian follicle development and triggering ovulation. - The drug is typically given by subcutaneous injection and is often used with follicle-stimulating hormone. - The report highlights rising use of hormone-based fertility treatments, assisted reproductive technologies, personalized treatment protocols, combination hormone therapies and more precise ovulation induction techniques as key trends. - A major market driver is the increasing rate of infertility worldwide, which can be linked to delayed childbirth, lifestyle choices, environmental pollutants and underlying health issues. - The report points to UK data from July 2023 showing 52,400 patients underwent IVF at licensed fertility centers, up from previous years. - Births resulting from donor insemination reached about 820, also up from earlier figures. - Healthcare infrastructure expansion is also supporting market growth by improving access to fertility treatment and specialized infertility centers. - In May 2023, the UK government announced more than $25.33 billion (£20 billion) for the New Hospital Programme, which plans to build 40 new hospitals in England by 2030. - The report’s 2026 updates include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - More information is available in the full report and a free sample.

Between the lines: - The report frames Luveris as a niche drug with demand pulled by structural fertility trends rather than a single short-term catalyst. - The emphasis on personalized medicine and combination therapies suggests fertility care is becoming more tailored, which could support broader use of hormone-based products. - North America’s lead likely reflects mature fertility care infrastructure, while Asia-Pacific’s growth outlook points to rising access and awareness rather than market saturation.

What's next: - The Luveris market is expected to keep growing through 2035 as fertility treatment demand expands and clinics adopt more advanced hormonal protocols. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa, indicating a global market with uneven regional adoption.

The bottom line: - Luveris is positioned to benefit from long-term demand in fertility care, with growth tied to infertility prevalence, expanding treatment infrastructure and more sophisticated reproductive medicine.